West Pharmaceutical Services revenue and financials
$372.64Change from previous close: −1.09%Absolute change: −$4.12
In the fiscal year ended December 2025, West Pharmaceutical Services reported revenue of $3.07B (+6.25% year over year). Net income was $493.7M, a net margin of 16.1%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +6.25%
- 2025 vs 2024
- Net income growth
- +0.20%
- 2025 vs 2024
- Net margin
- 16.1%
- 2024: 17.0%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 755 | 653 | 777 | 724 | 584 | 473 | 367 | 289 | 263 | 219 |
| Depreciation and amortization | 171 | 155 | 137 | 121 | 122 | 109 | 103 | 104 | 96.7 | 90.7 |
| Capital expenditure | -286 | -377 | -362 | -285 | -253 | -174 | -126 | -105 | -131 | -170 |
| Investing cash flow | -286 | -379 | -369 | -288 | -253 | — | — | — | — | — |
| Financing cash flow | -185 | -623 | -460 | -294 | -168 | — | — | — | — | — |
| Dividends paid | -61.2 | -59.1 | -57.0 | -54.1 | -51.1 | -48.1 | -45.1 | -42.1 | -39.1 | -35.8 |
| Share repurchases | -134 | -561 | -438 | -203 | -137 | -116 | -83.1 | -70.8 | -74.4 | -52.2 |
| Debt issued | 0.0 | 165 | 0.0 | 0.0 | — | — | — | — | — | — |
| Debt repaid | -1.1 | -192 | -2.4 | -44.3 | -2.2 | — | — | — | — | — |
| Effect of exchange rates | 22.9 | -21.4 | 11.4 | -10.5 | -15.7 | — | — | — | — | — |
| Net change in cash | 307 | -369 | -40.4 | 132 | 147 | — | — | — | — | — |
| Free cash flow | 469 | 276 | 415 | 439 | 331 | — | — | — | — | — |
| Levered free cash flow | 274 | 207 | 196 | 247 | 210 | — | — | — | — | — |